Johnson & Johnson Amendment to Schedule 13G for Rapport Therapeutics

Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation-JJDC, Inc. (JJDC), have filed an Amendment No. 1 to Schedule 13G for Rapport Therapeutics, Inc. The amendment reports that J&J and JJDC beneficially own 1,784,517 shares of Rapport Therapeutics' common stock, representing 4.9% of the outstanding shares. The shares are directly owned by JJDC, with J&J indirectly beneficially owning them. The filing is a joint submission under Rule 13d-1(d) and updates the previous Schedule 13G filed on October 18, 2024. The percentage ownership is based on 36,497,920 shares of common stock outstanding as of August 4, 2025.